Pramipexole and levodopa in early Parkinson's disease : Dynamic changes in cost effectiveness - NOYES, Katia; DICK, Andrew W; HOLLOWAY, Robert G (PharmacoEconomics, 2005)
Keywords: Administration, Oral; Adult; Anticonvulsants. Antiepileptics. Antiparkinson agents; Antiparkinson Agents - administration & dosage; Antiparkinson Agents - economics; Antiparkinson Agents - therapeutic use; Benzothiazoles; Biological and medical sciences; carbidopa; Cost-Benefit Analysis - methods; Cost-utility; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Double-Blind Method; Female; Health Expenditures - statistics & numerical data; Humans; Levodopa; Levodopa - administration & dosage; Levodopa - economics; Levodopa - therapeutic use; Male; Medical sciences; Nervous system (semeiology, syndromes); Nervous system as a whole; Neurology; Neuropharmacology; Parkinson Disease - diagnosis; Parkinson Disease - drug therapy; Parkinson Disease - economics; Parkinson's-disease; Pharmacology. Drug treatments; Pramipexole; Prospective Studies; Reproducibility of Results; Sex Factors; Thiazoles - administration & dosage; Thiazoles - economics; Thiazoles - therapeutic use; Time Factors; Treatment Outcome; Human; Agonist; Nervous system diseases; Costs; Parkinson disease; Duration; Neuroprotective agent; Antiparkinson agent; Long term; Pramipexole; Cerebral disorder; Chemotherapy; D2 Dopamine receptor; Treatment; Price; Health economy; Dopamine agonist; Central nervous system disease; Early; Degenerative disease; Levodopa; Public health; Extrapyramidal syndrome; Cost efficiency analysis